Stocktoria
GALECTIN THERAPEUTICS INC GALT
GALECTIN THERAPEUTICS INC financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D expense | $14.3M | $36.6M | $32.1M | $31.7M | $23.8M | $18.0M | $7.5M | $6.5M | $11.7M | $15.3M |
| Operating income | -$20.1M | -$42.4M | -$38.1M | -$38.4M | -$30.2M | -$23.4M | -$13.4M | -$13.6M | -$16.2M | -$21.5M |
| Interest expense | — | — | $2.8M | $1.0M | $489,000 | $87,000 | $87,000 | $336,000 | $12,000 | — |
| Income tax | $0 | $0 | — | — | — | — | — | — | — | — |
| Net income | -$30.8M | -$47.0M | -$41.1M | -$38.8M | -$30.5M | -$23.5M | -$13.3M | -$13.9M | -$16.2M | -$21.4M |
| EPS (diluted) | $-0.48 | $-0.76 | $-0.74 | $-0.65 | $-0.52 | $-0.41 | — | — | — | — |
| Operating cash flow | -$23.9M | -$41.8M | -$33.0M | -$31.1M | -$24.3M | -$20.6M | -$10.8M | -$10.2M | -$15.9M | -$16.4M |
| Cash & equivalents | $17.7M | $15.1M | $25.7M | $18.6M | $39.6M | $27.1M | $47.5M | $8.3M | $3.1M | $15.4M |
| Total assets | $19.5M | $17.5M | $28.2M | $21.3M | $41.8M | $29.6M | $48.5M | $9.0M | $4.2M | $15.8M |
| Total liabilities | $145.7M | $120.6M | $88.4M | $53.5M | $39.2M | $5.4M | $2.9M | $2.1M | $3.0M | $3.8M |
| Shareholders' equity | -$127.9M | -$104.8M | -$62.0M | -$33.9M | $893,000 | $22.5M | $43.9M | $5.2M | -$530,000 | $10.3M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.